195 related articles for article (PubMed ID: 27372542)
1. Efficacy of Double Bronchodilation (LABA+LAMA) in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Lung Cancer.
Leiro-Fernández V; Priegue Carrera A; Fernández-Villar A
Arch Bronconeumol; 2016 Dec; 52(12):622-623. PubMed ID: 27372542
[No Abstract] [Full Text] [Related]
2. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Patalano F; Banerji D
COPD; 2016 Dec; 13(6):686-692. PubMed ID: 27715335
[TBL] [Abstract][Full Text] [Related]
4. [The combination of indacaterol and glycopyrronium has effects on symptoms, lung function, and rate of exacerbations in COPD patients].
Ulrik CS
Ugeskr Laeger; 2014 Sep; 176(38):. PubMed ID: 25294211
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
[TBL] [Abstract][Full Text] [Related]
6. Indacaterol/glycopyrronium: a dual bronchodilator for COPD.
Banerji D; Fogel R; Patalano F
Drug Discov Today; 2018 Jan; 23(1):196-203. PubMed ID: 29079130
[TBL] [Abstract][Full Text] [Related]
7. Dual bronchodilator therapy for chronic obstructive pulmonary disease: evidence for the efficacy and Safety of fixed dose combination treatments in the setting of recent guideline updates.
Deas SD; Huprikar N
Curr Opin Pulm Med; 2018 Mar; 24(2):130-137. PubMed ID: 29206657
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and functional impact of perioperative LAMA/LABA inhaled therapy in patients with lung cancer and chronic obstructive pulmonary disease.
Azuma Y; Sano A; Sakai T; Koezuka S; Otsuka H; Tochigi N; Isobe K; Sakamoto S; Takai Y; Iyoda A
BMC Pulm Med; 2021 May; 21(1):174. PubMed ID: 34020622
[TBL] [Abstract][Full Text] [Related]
9. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
[TBL] [Abstract][Full Text] [Related]
10. [LAMA/LABA fixed dose combination for treatment of COPD].
Kuwahira I
Nihon Rinsho; 2016 May; 74(5):820-6. PubMed ID: 27254953
[TBL] [Abstract][Full Text] [Related]
11. Dual use of bronchodilators versus monotherapy, and its impact on pulmonary rehabilitation in COPD patients.
Benavides-Cordoba V; Aviles S; Ascuntar C; Orozco L; Mosquera R; Rivera J
Pulm Pharmacol Ther; 2020 Apr; 61():101898. PubMed ID: 31978547
[TBL] [Abstract][Full Text] [Related]
12. Seebri Neohaler and Utibron Neohaler for COPD.
Med Lett Drugs Ther; 2016 Mar; 58(1491):39-41. PubMed ID: 27027687
[No Abstract] [Full Text] [Related]
13. Relationship between lung function and inhalation devices for LAMA/LABA therapy for chronic obstructive pulmonary disease.
Yamada H; Hida N; Satoh H; Nakaizumi T; Terashima H; Hizawa N
Chron Respir Dis; 2018 Nov; 15(4):419-420. PubMed ID: 29152998
[No Abstract] [Full Text] [Related]
14. Glycopyrronium + indacaterol. A fixed-dose combination with no advantages in COPD.
Prescrire Int; 2014 Dec; 23(155):288. PubMed ID: 25629143
[TBL] [Abstract][Full Text] [Related]
15. Another Choice for Prevention of COPD Exacerbations.
Donohue JF
N Engl J Med; 2016 Jun; 374(23):2284-6. PubMed ID: 27181835
[No Abstract] [Full Text] [Related]
16. [Indacaterol (Onbrez Breezhaler), oral inhalation].
Duh D; Tanret I
J Pharm Belg; 2011 Dec; (4):127-8. PubMed ID: 22299240
[No Abstract] [Full Text] [Related]
17. Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease.
Pleasants RA
Ann Pharmacother; 2019 Mar; 53(3):285-293. PubMed ID: 30175596
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
[TBL] [Abstract][Full Text] [Related]
19. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
Prakash A; Babu KS; Morjaria JB
Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
[TBL] [Abstract][Full Text] [Related]
20. Preoperative management using inhalation therapy for pulmonary complications in lung cancer patients with chronic obstructive pulmonary disease.
Takegahara K; Usuda J; Inoue T; Ibi T; Sato A
Gen Thorac Cardiovasc Surg; 2017 Jul; 65(7):388-391. PubMed ID: 28281043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
